Titrated extract of Centella asiatica (TECA) in the treatment of venous insufficiency of the lower limbs.
Ninety-four patients suffering from venous insufficiency of the lower limbs participated in a multicenter, double-blind versus placebo study. After randomization, they were allotted for a treatment period of two months to one of three groups: TECA 120 mg/day, TECA 60 mg/day, or placebo. A significant difference (p less than 0.05) in favor of TECA was shown for the symptoms of heaviness in the lower limbs and edema, as well as for the overall evaluation by the patient. The venous distensibility measured by a mercury strain gauge plethysmograph at three occlusion pressures was improved for the TECA groups but aggravated for the placebo group.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007866:Leg / Q000098:blood supply; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011897:Random Allocation; D014315:Triterpenes / Q000009:adverse effects / Q000627:therapeutic use*; D014689:Venous Insufficiency / Q000188:drug therapy*
D010919:Placebos; C005084:TECA; D014315:Triterpenes